Mechanistic Modeling in Biotherapeutic Drug Development
Mechanistic modeling is revolutionizing biotherapeutic drug development with the goal of getting new medicines to patients faster, more reliably and more cost-effectively.
Stefan Walke, Global Head of Alliance Management, dzieli się swoimi spostrzeżeniami dotyczącymi zarządzania aliansami i jego wkładem w rozwój udanych i długotrwałych partnerstw.
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
Antibody therapeutics business partnering PetMedix
Combining PetMedix’ expertise in veterinary biotherapeutic technology with Boehringer Ingelheim’s long experience and innovation in human antibody discovery and development provides a unique opportunity for the partners.